Shares of Dermira Inc (NASDAQ:DERM) plunged hard Monday, after the drug maker announced negative Phase 3 data for its acne drug, DRM01, thus leading …
Dermira loses a bull after not one, but two pivotal studies of DRM01 in acne bombed.
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …
